Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast.

@article{Leonard1987MitoxantroneVD,
  title={Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast.},
  author={Robert C. F. Leonard and Michael A. Cornbleet and Stanley B. Kaye and Michael Soukop and Greg White and Andrew W. Hutcheon and Susan Robinson and Mary E. Kerr and John F. Smyth},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1987},
  volume={5 7},
  pages={1056-63}
}
One hundred fifteen patients with metastatic carcinoma of the breast were treated in a randomized trial of mitoxantrone (Novantrone, Lederle Laboratories, Pearl River, NY) combined with vincristine and prednisolone (VMP) or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) combined with vincristine and prednisolone (VAP). In 100 evaluable patients, the objective response rates were 35% for VMP and 61% for VAP, the complete response rates being 6% and 13%, respectively. In responding… CONTINUE READING

Similar Papers

Loading similar papers…